scispace - formally typeset
M

Marco Folini

Researcher at University of Milan

Publications -  85
Citations -  9505

Marco Folini is an academic researcher from University of Milan. The author has contributed to research in topics: Telomere & Telomerase. The author has an hindex of 38, co-authored 83 publications receiving 8798 citations. Previous affiliations of Marco Folini include National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

miR-205 Exerts Tumor-Suppressive Functions in Human Prostate through Down-regulation of Protein Kinase Cε

TL;DR: Overall, it is shown for the first time that miR-205 exerts a tumor-suppressive effect in human prostate by counteracting epithelial-to-mesenchymal transition and reducing cell migration/invasion, at least in part through the down-regulation of protein kinase Cepsilon.
Journal ArticleDOI

Targeting survivin in cancer therapy: fulfilled promises and open questions.

TL;DR: Survivin is a bifunctional protein that acts as a suppressor of apoptosis and plays a central role in cell division and has been proposed as an attractive target for new anticancer interventions as discussed by the authors.
Journal ArticleDOI

miR-21: an oncomir on strike in prostate cancer

TL;DR: Evidence is provided that miR-21 knockdown in prostate cancer cells is not sufficient per se to affect the proliferative and invasive potential or the chemo- and radiosensitivity profiles, which supports the notion that the oncogenic properties of mi R-21 could be cell and tissue dependent and that the potential role of a given miRNA as a therapeutic target should be contextualized with respect to the disease.
Journal ArticleDOI

Targeting survivin in cancer therapy

TL;DR: Several preclinical studies have demonstrated that downregulation of survivin expression or function, accomplished by means of various strategies, reduced tumor growth potential, increased the apoptotic rate and sensitized tumor cells to chemotherapeutic drugs and radiation in different human tumor models.